PharmaVentures partnered with Informa to deliver a live panel discussion during CPhI Worldwide in the form of a webinar.This webinar focuses on the future of broader outsourced contract services in the Pharmaceutical Industry, which spans the Contract Development...

Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market. With multiple vaccines now approved and being...

Hard lessons from 30 years of experience  A conversation with Fintan Walton, Founder of PharmaVentures Tony Jones, Chief Executive of One Nucleus, caught up with Fintan Walton to discuss the evolution of the deal making processes, where it is going in the...

Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key...

In this special edition of PharmaVentures Insights, Dr Fintan Walton, CEO & Founder of PharmaVentures, leads a panel discussion to address whether a dual fundraising and partnering strategy is the best way forward for an emerging biotech. Panelists...

In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm. Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in...

Can Partnering Conference Cancellations Affect Dealmaking in 2020? We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we...

In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome. Paul Larsmon spoke with leading...

The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals....

What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of...

Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...

With more than 89 million chronic disease sufferers in the US alone, NetScienctific is focused on fighting chronic diseases on three fronts to create 'next generation healthcare technologies'. Thier healthcare investment strategy is building businesses in digital...